Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Health Law (2)
- Intellectual Property (2)
- Torts (2)
- Bioethics (1)
- Biopharmaceutical Companies (1)
-
- Biopharmaceutical Products (1)
- Business Ethics (1)
- CDTR (1)
- CFAA (1)
- Charitable Activity (1)
- Coercion (1)
- Common Law (1)
- Competition (1)
- Computer Fraud and Abuse Act (1)
- Consumer Data Trafficking (1)
- Contracts (1)
- Corporate Duty To Rescue (1)
- Criminal Law (1)
- Disabling Choice (1)
- Disparate Treatment Law (1)
- Education (1)
- Employment Law (1)
- Environmental Law (1)
- Estates (1)
- Executive Compensation (1)
- FCRA (1)
- FDA (1)
- FIPPs (1)
- FTC (1)
- Fair Credit Reporting Act (1)
Articles 1 - 3 of 3
Full-Text Articles in Law
Money That Costs Too Much: Regulating Financial Incentives, Kristen Underhill
Money That Costs Too Much: Regulating Financial Incentives, Kristen Underhill
Indiana Law Journal
Money may not corrupt. But should we worry if it corrodes? Legal scholars in a range of fields have expressed concern about “motivational crowding-out,” a process by which offering financial rewards for good behavior may undermine laudable social motivations, like professionalism or civic duty. Disquiet about the motivational impacts of incentives has now extended to health law, employment law, tax, torts, contracts, criminal law, property, and beyond. In some cases, the fear of crowding-out has inspired concrete opposition to innovative policies that marshal incentives to change individual behavior. But to date, our fears about crowding-out have been unfocused and amorphous; …
A Corporate Duty To Rescue: Biopharmaceutical Companies And Access To Medications, Rebecca E. Wolitz
A Corporate Duty To Rescue: Biopharmaceutical Companies And Access To Medications, Rebecca E. Wolitz
Indiana Law Journal
Controversies regarding the pricing of biopharmaceutical products are pervasive. Patients must choose between treatment and rent, prescriptions go unfilled, and health systems are forced to restrict access to life-saving medications— all because of cost. Though there is often consensus that these issues are problematic, there is disagreement as to what are appropriate solutions and who has responsibility to bring about those solutions. Most efforts to address biopharmaceutical pricing concerns focus on governmental regulation. This Article has a different focus. It provides a legal and normative analysis of a form of corporate self-regulation that could help address access and pricing concerns—a …
Privacy Remedies, Lauren H. Scholz
Privacy Remedies, Lauren H. Scholz
Indiana Law Journal
When consumers sue companies for privacy-intrusive practices, they are often unsuccessful. Many cases fail in federal court at the motion to dismiss phase because the plaintiff has not shown the privacy infringement has caused her concrete harm. This is a symptom of a broader issue: the failure of courts and commentators to describe the relationship between privacy rights and privacy remedies.
This Article contends that restitution is the normal measure of privacy remedies. Restitution measures relief by economic gain to the defendant. If a plaintiff can show the likely ability to recover in restitution, that should be sufficient to pass …